Very Low Birth Weight Outcomes of the National Institute of Child Health and Human Development Neonatal Network

PEDIATRICS ◽  
1991 ◽  
Vol 87 (5) ◽  
pp. 587-597 ◽  
Author(s):  
Maureen Hack ◽  
Jeffrey D. Horbar ◽  
Michael H. Malloy ◽  
Linda Wright ◽  
Jon E. Tyson ◽  
...  

This report describes the neonatal outcomes of 1765 very low birth weight (<1500 g) infants delivered from November 1987 through October 1988 at the seven participating centers of the National Institute of Child Health and Human Development Neonatal Intensive Care Network. Survival was 34% at <751 g birth weight (range between centers 20% to 55%), 66% at 751 through 1000 g (range 42% to 75%), 87% at 1001 through 1250 g (range 84% to 91%), and 93% at 1251 through 1500 g (range 89% to 98%). By obstetric measures of gestation, survival was 23% at 23 weeks (range 0% to 33%), 34% at 24 weeks (range 10% to 57%), and 54% at 25 weeks (range 30% to 72%). Neonatal morbidity included respiratory distress (67%), symptomatic patent ductus arteriosus (25%), necrotizing enterocolitis (6%), septicemia (17%), meningitis (2%), urinary tract infection (4%), and intraventricular hemorrhage (45%, 18% grade III and IV). Morbidity increased with decreasing birth weight. Oxygen was administered for ≥28 days to 79% of <751-g birth weight infants (range between centers 67% to 100%), 45% of 751-through 1000-g infants (range 20% to 68%), and 13% of 1001- through 1500-g infants (range 5% to 23%). Ventilator support for ≥28 days was given to 68% of infants at <751 g, 29% at 751 through 1000 g, and 4% at >1000 g. Hospital stay was 59 days for survivors vs 15 days for infants who died. Sixty-nine percent of survivors had subnormal (<10th percentile) weight at discharge. The data demonstrate important intercenter variation of current neonatal outcomes, as well as differences in philosophy of care and definition and prevalence of morbidity.

PEDIATRICS ◽  
1991 ◽  
Vol 88 (4) ◽  
pp. 880-880

To the Editor.— The authors of the National Institute of Child Health and Human Development Neonatal Research network report1 of very low birth weight outcomes deserve a lot of praise for providing a survey of neonatal practices. But they are much too polite. In the discussion of "important intercenter variation as well as differences in the philosophy of care," the authors mildly note, "the practice of neonatal medicine remains in part an art rather than an exact science."


1995 ◽  
Vol 173 (5) ◽  
pp. 1423-1431 ◽  
Author(s):  
Avroy A. Fanaroff ◽  
Lindal L. Wright ◽  
David K. Stevenson ◽  
Seetha Shankaran ◽  
Edward P. Donovan ◽  
...  

1995 ◽  
Vol 172 (2) ◽  
pp. 457-464 ◽  
Author(s):  
Maureen Hack ◽  
Linda L. Wright ◽  
Seetha Shankaran ◽  
Jon E. Tyson ◽  
Jeffrey D. Horbar ◽  
...  

2005 ◽  
Vol 24 (4) ◽  
pp. 45-48 ◽  
Author(s):  
Susan Givens Bell

SEPSIS CONTINUES TO BE A significant cause of neonatal morbidity and mortality. In a recent study by the National Institute of Child Health and Human Development Neonatal Research Network, 21 percent of very low birth weight neonates older than three days of age had one or more episodes of proven bloodstream sepsis (range for the 15 network centers: 11–32 percent). The study’s authors assert that strategies to decrease the incidence of nosocomial infection and the related social and economic impact are urgently needed.1 Researchers have been exploring various modalities, including immunomodulation, as adjuncts to antibiotics to enhance the neonatal immune system. Generally, immunomodulators act to stimulate or augment the immune system indirectly.


PEDIATRICS ◽  
1992 ◽  
Vol 89 (2) ◽  
pp. 357-357
Author(s):  
HELEN HARRISON

To the Editor.— The authors of the National Institute of Child Health and Human Development report on neonatal care1 found "important" variations among neonatal intensive care units in philosophies of treatment, methods of treatment, and short-term outcomes. In a recent meta-analysis of follow-up studies,2 researchers document a similarly haphazard approach to the long-term evaluation of very low birth weight survivors. Until randomized controlled clinical trials validate the safety and efficacy of neonatal therapies, and until long-term outcomes are assessed accurately, the treatment of very low birth weight infants should be declared experimental.


2021 ◽  
Vol 16 ◽  
Author(s):  
Ufuk Cakir ◽  
Cuneyt Tayman

Background: Patent ductus arteriosus (PDA) is associated with adverse clinical outcomes in very low birth weight (<1500g) infants. Objective: In our study, it was aimed to investigate the effect of gentamicin treatment, which is frequently used for early-onset sepsis on ductal patency. Method: We performed a single-center retrospective review of charts of preterm infants <32 weeks gestation with birth weight <1500 grams born between June 1, 2015, and December 31, 2019, at the neonatal intensive care unit. All infants underwent an echocardiogram (ECHO) at 72 hours. To determine the effect of gentamicin treatment on hemodynamically significant PDA (hsPDA), we compared the frequency and duration of gentamicin administration between infants with hsPDA and without hsPDA. Results: During the study period, 792 patients were evaluated. Gentamicin was given to more infants with hsPDA than to those without hsPDA (89.2 % vs. 64.6 %, p<0.001), and the duration of therapy was longer in those infants with hsPDA (7 days vs. 9 days, p<0.001). The area under the curve for duration of gentamicin was 0.772 (%95 CI: 0.742-0.804, P=0.0001), sensitivity: 59 (%95 CI: 53-65), specificity: 82 (%95 CI: 78-88), with a cut-off day for duration of gentamicin >7 days. Conclusion: In our study, it was found that ductal contraction decreased and hsPDA rate increased as the rate and duration of gentamicin increased.


PEDIATRICS ◽  
1993 ◽  
Vol 91 (3) ◽  
pp. 540-545
Author(s):  

This report describes the Vermont-Oxford Trials Network, a voluntary collaborative research network, and summarizes the outcomes and medical interventions for very low birth weight infants at participating centers in 1990. The Vermont-Oxford Trials Network included 36 centers in 1990 (11% university hospitals, 44% university affiliates, 44% nonaffiliated) with a total of 2961 infants weighing 501 to 1500 g (median 73 infants, range 5 to 172). Eighty percent of the infants were inborn and 65% were white. The overall network frequencies for selected interventions and outcomes were as follows: prenatal care, 90%; a complete course of antenatal corticosteroids, 12%; cesarean section, 56%; surfactant therapy, 49%; postnatal steroids for chronic lung disease, 16%; high-frequency ventilation, 4%; patent ductus arteriosus, 31%; necrotizing enterocolitis, 6%; bacterial sepsis, 16%; and intraventricular hemorrhage, 26%. By 28 days, 15% of the infants had died and 8% had been transferred, whereas by discharge 18% had died and 18% had been transferred. There were marked variations among the centers in the frequencies of different medical interventions and in the frequencies of various clinical outcomes. The Vermont-Oxford Trials Network is a unique collaborative research group composed of a broad range of neonatal intensive care units. During 1990 there were considerable differences among the centers in the interventions used and patient outcomes observed. The investigators plan to devote the resources of the Network to a research program of randomized trials and outcome studies so that effective interventions can be identified and the quality of neonatal intensive care can be continuously improved.


Sign in / Sign up

Export Citation Format

Share Document